Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Liquid biopsy, big data and artificial intelligence as a new global clinical trial model in targeted therapy
3
Zitationen
6
Autoren
2023
Jahr
Abstract
To this day, the phase III trial continues to be, as it was more than 60 years ago, the standard for the incorporation of new treatments in oncology. We currently have new tools such as NGS, Liquid Biopsy (LB), Big Data (BD) and Artificial Intelligence (AI) that will allow us to move towards faster and more universal research. This article analyzes the important weaknesses of phase III trials, the importance and current status of targeted therapy, and the contributions to LB decision-making and the knowledge of what happens in real life (RWD) that we facilitates BD and AI. Finally, what could be a clinical trial model that would take advantage of all these tools is proposed.
Ähnliche Arbeiten
Explainable Artificial Intelligence (XAI): Concepts, taxonomies, opportunities and challenges toward responsible AI
2019 · 8.316 Zit.
Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead
2019 · 8.177 Zit.
High-performance medicine: the convergence of human and artificial intelligence
2018 · 7.575 Zit.
Proceedings of the 19th International Joint Conference on Artificial Intelligence
2005 · 5.776 Zit.
Peeking Inside the Black-Box: A Survey on Explainable Artificial Intelligence (XAI)
2018 · 5.468 Zit.